These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25336117)

  • 1. A novel germline mutation of PDGFR-β might be associated with clinical response of colorectal cancer to regorafenib.
    Rechsteiner M; Wild P; Kiessling MK; Bohnert A; Zhong Q; Stahel RA; Moch H; Curioni-Fontecedro A
    Ann Oncol; 2015 Jan; 26(1):246-248. PubMed ID: 25336117
    [No Abstract]   [Full Text] [Related]  

  • 2. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hypothyroidism caused by apatinib in patient with lung metastasis from rectal adenocarcinoma: a case report].
    Chen XR; Chang Z; Wang HQ
    Zhonghua Zhong Liu Za Zhi; 2019 Dec; 41(12):959-960. PubMed ID: 31874556
    [No Abstract]   [Full Text] [Related]  

  • 4. Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report.
    Callebout E; Ribeiro SM; Laurent S; De Man M; Ferdinande L; Claes KBM; Van der Meulen J; Geboes KP
    BMC Cancer; 2019 Jun; 19(1):567. PubMed ID: 31185985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report.
    Yoshino K; Manaka D; Kudo R; Kanai S; Mitsuoka E; Kanto S; Hamasu S; Konishi S; Nishitai R
    J Med Case Rep; 2017 Aug; 11(1):227. PubMed ID: 28818109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A Patient with Cavitated Pulmonary Metastases Treated with Regorafenib].
    Taniguchi M; Mori M; Sata N; Fujii H
    Gan To Kagaku Ryoho; 2016 Jun; 43(6):757-9. PubMed ID: 27306815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.
    Ducreux M; Petersen LN; Öhler L; Bergamo F; Metges JP; de Groot JW; Wang JY; García Paredes B; Dochy E; Fiala-Buskies S; Cervantes A; O'Connor JM; Falcone A;
    Eur J Cancer; 2019 Dec; 123():146-154. PubMed ID: 31698328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib.
    Ettrich TJ; Seufferlein T
    Recent Results Cancer Res; 2014; 201():185-96. PubMed ID: 24756792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regorafenib in metastatic colorectal cancer.
    Grothey A
    Clin Adv Hematol Oncol; 2012 May; 10(5):324-5. PubMed ID: 22706543
    [No Abstract]   [Full Text] [Related]  

  • 10. Circulating DNA biomarkers: a primer for metastatic colorectal cancer?
    Eng C
    Lancet Oncol; 2015 Aug; 16(8):878-9. PubMed ID: 26184521
    [No Abstract]   [Full Text] [Related]  

  • 11. Regorafenib for metastatic colorectal cancer.
    Ricotta R; Sartore-Bianchi A; Verrioli A; Vanzulli A; Siena S
    Lancet; 2013 May; 381(9877):1537. PubMed ID: 23642696
    [No Abstract]   [Full Text] [Related]  

  • 12. Regorafenib for metastatic colorectal cancer.
    Hyun MH; Shin MR; Kim YH
    Lancet; 2013 May; 381(9877):1537-8. PubMed ID: 23642695
    [No Abstract]   [Full Text] [Related]  

  • 13. Regorafenib for metastatic colorectal cancer.
    André T; Raymond E; de Gramont A
    Lancet; 2013 May; 381(9877):1536-7. PubMed ID: 23642693
    [No Abstract]   [Full Text] [Related]  

  • 14. Capecitabine plus temozolomide (CapTem): An alternative regimen to regorafenib as third-line setting in metastatic colorectal cancer?
    Ergun Y; Bal O; Dogan M; Uncu D
    J BUON; 2019; 24(6):2435-2441. PubMed ID: 31983117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA approves regorafenib (Stivarga) for metastatic colorectal cancer.
    Oncology (Williston Park); 2012 Oct; 26(10):896. PubMed ID: 23175993
    [No Abstract]   [Full Text] [Related]  

  • 16. Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models.
    Daudigeos-Dubus E; Le Dret L; Lanvers-Kaminsky C; Bawa O; Opolon P; Vievard A; Villa I; Pagès M; Bosq J; Vassal G; Zopf D; Geoerger B
    PLoS One; 2015; 10(11):e0142612. PubMed ID: 26599335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regorafenib in metastatic colorectal cancer.
    Sartore-Bianchi A; Zeppellini A; Amatu A; Ricotta R; Bencardino K; Siena S
    Expert Rev Anticancer Ther; 2014 Mar; 14(3):255-65. PubMed ID: 24559322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regorafenib for metastatic colorectal cancer - Authors' reply.
    Van Cutsem E; Grothey A
    Lancet; 2013 May; 381(9877):1538-9. PubMed ID: 23642697
    [No Abstract]   [Full Text] [Related]  

  • 19. mRNA expression of platelet-derived growth factor receptor-beta and C-KIT: correlation with pathologic response to cetuximab-based chemoradiotherapy in patients with rectal cancer.
    Erben P; Horisberger K; Muessle B; Müller MC; Treschl A; Ernst T; Kähler G; Ströbel P; Wenz F; Kienle P; Post S; Hochhaus A; Willeke F; Hofheinz RD
    Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1544-50. PubMed ID: 19028276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
    Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
    Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.